MA33538B1 - Nouveaux antagonistes pyrimidine et triazine de l'hepcidine - Google Patents
Nouveaux antagonistes pyrimidine et triazine de l'hepcidineInfo
- Publication number
- MA33538B1 MA33538B1 MA34652A MA34652A MA33538B1 MA 33538 B1 MA33538 B1 MA 33538B1 MA 34652 A MA34652 A MA 34652A MA 34652 A MA34652 A MA 34652A MA 33538 B1 MA33538 B1 MA 33538B1
- Authority
- MA
- Morocco
- Prior art keywords
- hepsidin
- triazine
- pyrimidine antagonists
- new pyrimidine
- anemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/66—Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne de nouveaux antagonistes de l'hepcidine de formule (I), des compositions pharmaceutiques les comprenant ainsi que leur utilisation comme médicament, en particulier pour le traitement de troubles du métabolisme du fer, comme en particulier les maladies de carence en fer et les anémies, en particulier les anémies en liaison avec des maladies inflammatoires chroniques (ACD : anémie de maladie chronique et AI : anémie d'inflammation).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09169286 | 2009-09-02 | ||
PCT/EP2010/062708 WO2011026835A1 (fr) | 2009-09-02 | 2010-08-31 | Nouveaux antagonistes pyrimidine et triazine de l'hepcidine |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33538B1 true MA33538B1 (fr) | 2012-08-01 |
Family
ID=41490366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34652A MA33538B1 (fr) | 2009-09-02 | 2012-02-27 | Nouveaux antagonistes pyrimidine et triazine de l'hepcidine |
Country Status (21)
Country | Link |
---|---|
US (1) | US20120202806A1 (fr) |
EP (1) | EP2473486B2 (fr) |
JP (1) | JP2013503833A (fr) |
KR (1) | KR20120061055A (fr) |
CN (1) | CN102482232A (fr) |
AR (1) | AR077999A1 (fr) |
AU (1) | AU2010291318A1 (fr) |
BR (1) | BR112012008109A2 (fr) |
CA (1) | CA2769553A1 (fr) |
CL (1) | CL2012000591A1 (fr) |
CR (1) | CR20120097A (fr) |
DO (1) | DOP2012000057A (fr) |
EA (1) | EA201200402A1 (fr) |
ES (1) | ES2554855T3 (fr) |
IL (1) | IL218253A0 (fr) |
MA (1) | MA33538B1 (fr) |
MX (1) | MX2012002626A (fr) |
SG (1) | SG178984A1 (fr) |
TN (1) | TN2012000045A1 (fr) |
TW (1) | TW201113272A (fr) |
WO (1) | WO2011026835A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
DE102010002558A1 (de) * | 2009-11-20 | 2011-06-01 | Symrise Ag | Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe |
ES2587232T3 (es) | 2010-07-20 | 2016-10-21 | Vestaron Corporation | Triazinas y pirimidinas insecticidas |
CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
EP2771337B1 (fr) | 2011-09-27 | 2017-08-02 | Novartis AG | 3-(pyrimidin-4-yl)-oxazolidin-2-ones comme inhibiteurs d'idh mutante |
JP2014237590A (ja) * | 2011-09-30 | 2014-12-18 | アステラス製薬株式会社 | 2−(ピリジン−2−イル)ピリミジン−4−アミン化合物又はその塩 |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
HUE054031T2 (hu) | 2012-04-24 | 2021-08-30 | Vertex Pharma | DNS-PK inhibitorok |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
CA2896731A1 (fr) * | 2012-12-28 | 2014-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibiteurs du complexe usp1/uaf1 desubiquitinase et leurs utilisations |
JP6120311B2 (ja) * | 2013-02-12 | 2017-04-26 | 学校法人銀杏学園 | ポリフェノール化合物 |
HUE041544T2 (hu) | 2013-03-12 | 2019-05-28 | Vertex Pharma | DNS-PK inhibitorok |
CA2903979A1 (fr) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante |
EP3046912A1 (fr) | 2013-09-16 | 2016-07-27 | Bayer Pharma Aktiengesellschaft | Trifluorométhylpyrimidones disubstituées et leur utilisation comme antagonistes du ccr2 |
SI3057953T1 (sl) | 2013-10-17 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Ko-kristali(s)-n-metil-8-(1-((2'-metil-(4,5'-bipimiridin)-6-il)amino) propan-2-il)kinolin-4-karboksamida in njegovi devterirani derivati kot inhibitorji dna-pk |
US10981899B2 (en) | 2016-04-28 | 2021-04-20 | Cornell University | Inhibitors of soluble adenylyl cyclase |
AU2017275657B2 (en) | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
CA3038657A1 (fr) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Methode de traitement du cancer utilisant une combinaison d'agents endommageant l'adn et d'inhibiteurs de la dna-pk |
CN110198935B (zh) | 2017-01-23 | 2022-05-31 | 卡登特治疗公司 | 钾通道调节剂 |
US10172856B2 (en) | 2017-04-06 | 2019-01-08 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives as histamine H4 modulators |
JP7231617B2 (ja) | 2017-08-31 | 2023-03-01 | ビーエーエスエフ ソシエタス・ヨーロピア | 生理学的冷涼活性成分の使用、及びそのような活性成分を含む組成物 |
MA53978A (fr) | 2018-10-22 | 2021-09-01 | Cadent Therapeutics Inc | Formes cristallines de modulateurs des canaux potassiques |
WO2021222359A1 (fr) * | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Thiénopyrimidines servant d'inhibiteurs de la ferroportine |
EP4143178A1 (fr) * | 2020-04-28 | 2023-03-08 | Global Blood Therapeutics, Inc. | Pyrimidines cycloalkyliques utilisées en tant qu'inhibiteurs de la ferroportine |
CA3181583A1 (fr) * | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Methodes d'utilisation de pyrimidines en tant qu'inhibiteurs de la ferroportine |
CN112028838B (zh) * | 2020-08-04 | 2022-07-01 | 精华制药集团南通有限公司 | 一种2-乙氧基-5-氟尿嘧啶杂质的制备方法 |
CN113683596B (zh) * | 2021-08-17 | 2023-02-10 | 上海应用技术大学 | 一种嘧啶类端锚聚合酶2抑制剂及其制备方法和应用 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993017009A1 (fr) * | 1992-02-28 | 1993-09-02 | Zenyaku Kogyo Kabushiki Kaisha | DERIVE DE s-TRIAZINE ET REMEDE CONTRE DES MALADIES DEPENDENTES DE L'×STROGENE LE CONTENANT COMME INGREDIENT ACTIF |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
US7166448B1 (en) | 1999-05-10 | 2007-01-23 | Children's Medical Center Corproation | Ferroportin1 nucleic acids and proteins |
JP4944360B2 (ja) | 2001-05-25 | 2012-05-30 | アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル(アンセルム) | 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 |
JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
DE60224223T2 (de) * | 2002-01-02 | 2008-12-04 | Actelion Pharmaceuticals Ltd. | Neue alkylsulfonamide als endothelinantagonisten |
TW200407315A (en) | 2002-04-23 | 2004-05-16 | Sankyo Co | Pyrimidine derivatives |
GB0226724D0 (en) | 2002-11-15 | 2002-12-24 | Merck Sharp & Dohme | Therapeutic agents |
EP1578254B1 (fr) | 2002-11-19 | 2013-03-06 | DRG International, Inc. | Methode diagnostique pour maladies par criblage d'hepcidine dans des tissus, du sang ou des fluides corporels humains ou animaux et utilisations therapeutiques |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
US7560464B2 (en) | 2004-04-13 | 2009-07-14 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
US7723063B2 (en) | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
JP2008513364A (ja) * | 2004-09-14 | 2008-05-01 | ザ ジェネティクス カンパニー,インコーポレイテッド | ヒドラゾン誘導体およびβ−セクレターゼインヒビターとしてのその使用 |
US20060161001A1 (en) | 2004-12-20 | 2006-07-20 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
GB0503962D0 (en) * | 2005-02-25 | 2005-04-06 | Kudos Pharm Ltd | Compounds |
US9771331B2 (en) * | 2005-04-22 | 2017-09-26 | The Johns Hopkins University | Methods of identifying neuroprotective compounds for retinal ganglion cells |
US20060293343A1 (en) | 2005-05-18 | 2006-12-28 | Asahi Kasei Pharma Corporation | Pyrimidine derivatives |
US7534764B2 (en) | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
US8258129B2 (en) | 2006-07-06 | 2012-09-04 | Boehringer Ingelheim International Gmbh | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
AU2007299629C1 (en) | 2006-09-21 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the HAMP gene |
CA2665438C (fr) | 2006-10-04 | 2014-12-02 | Tibotec Pharmaceuticals Ltd. | Carboxamide 4-[(4-pyridyl)amino]-pyrimidines utiles comme inhibiteurs de hcv |
WO2008088727A2 (fr) * | 2007-01-12 | 2008-07-24 | Concert Pharmaceuticals, Inc. | Antagonistes du récepteur de l'endothéline |
JP2010517529A (ja) | 2007-02-02 | 2010-05-27 | アムジエン・インコーポレーテツド | ヘプシジン及びヘプシジン抗体 |
TW200904437A (en) * | 2007-02-14 | 2009-02-01 | Janssen Pharmaceutica Nv | 2-aminopyrimidine modulators of the histamine H4 receptor |
DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
CL2008000666A1 (es) | 2007-03-07 | 2008-06-13 | Xenon Pharmaceuticals Inc | Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro. |
AR065785A1 (es) | 2007-03-19 | 2009-07-01 | Xenon Pharmaceuticals Inc | Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro |
PT2139882E (pt) | 2007-03-23 | 2014-01-30 | Amgen Inc | Derivados de quinolina ou quinoxalina 3-substituídos e sua utilização como inibidores de fosfatidilinositol 3-cinase (pi3k) |
WO2008121861A2 (fr) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Composés à base de pyrazole et de pyrrole utiles dans le traitement de troubles du métabolisme du fer |
JP2010208945A (ja) | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
CA2688547A1 (fr) | 2007-06-05 | 2008-12-11 | Xenon Pharmaceuticals, Inc. | Composes aromatiques et heteroaromatiques utiles dans le traitement de troubles du metabolisme du fer |
CN101903357A (zh) | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | 作为pkc抑制剂的环状胺取代的嘧啶二胺 |
GR1006896B (el) | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
JP5657383B2 (ja) | 2007-08-30 | 2015-01-21 | ダウ アグロサイエンシィズ エルエルシー | 2−(置換フェニル)−6−アミノ−5−アルコキシ、チオアルコキシ、およびアミノアルキル−4−ピリミジンカルボキシラート、ならびに除草剤としてのそれらの使用 |
CA2701694A1 (fr) | 2007-10-02 | 2009-04-09 | Sophie Vaulont | Anticorps specifiques a l'hepcidine humaine |
AR069062A1 (es) | 2007-11-02 | 2009-12-23 | Lilly Co Eli | Anticuerpo anti-hepcidina |
US20110124649A1 (en) * | 2007-11-09 | 2011-05-26 | The Johns Hopkins University | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
NZ586662A (en) * | 2007-12-19 | 2012-08-31 | Vertex Pharma | PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS |
WO2009093981A1 (fr) * | 2008-01-23 | 2009-07-30 | S Bio Pte Ltd | Composés de triazine comme inhibiteurs de la kinase |
CN101965177A (zh) | 2008-02-08 | 2011-02-02 | 株式会社资生堂 | 美白剂和皮肤外用剂 |
JP5557832B2 (ja) * | 2008-03-18 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 置換4−ヒドロキシピリジン−5−カルボキサミド |
AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
-
2010
- 2010-08-30 AR ARP100103174A patent/AR077999A1/es not_active Application Discontinuation
- 2010-08-31 AU AU2010291318A patent/AU2010291318A1/en not_active Abandoned
- 2010-08-31 JP JP2012527300A patent/JP2013503833A/ja active Pending
- 2010-08-31 SG SG2012015319A patent/SG178984A1/en unknown
- 2010-08-31 CN CN2010800389946A patent/CN102482232A/zh active Pending
- 2010-08-31 EA EA201200402A patent/EA201200402A1/ru unknown
- 2010-08-31 US US13/391,712 patent/US20120202806A1/en not_active Abandoned
- 2010-08-31 KR KR1020127008573A patent/KR20120061055A/ko not_active Application Discontinuation
- 2010-08-31 BR BR112012008109A patent/BR112012008109A2/pt not_active IP Right Cessation
- 2010-08-31 WO PCT/EP2010/062708 patent/WO2011026835A1/fr active Application Filing
- 2010-08-31 ES ES10747859.6T patent/ES2554855T3/es active Active
- 2010-08-31 EP EP10747859.6A patent/EP2473486B2/fr active Active
- 2010-08-31 MX MX2012002626A patent/MX2012002626A/es not_active Application Discontinuation
- 2010-08-31 CA CA2769553A patent/CA2769553A1/fr not_active Abandoned
- 2010-09-01 TW TW099129457A patent/TW201113272A/zh unknown
-
2012
- 2012-01-27 TN TNP2012000045A patent/TN2012000045A1/en unknown
- 2012-02-22 IL IL218253A patent/IL218253A0/en unknown
- 2012-02-27 CR CR20120097A patent/CR20120097A/es unknown
- 2012-02-27 MA MA34652A patent/MA33538B1/fr unknown
- 2012-03-01 DO DO2012000057A patent/DOP2012000057A/es unknown
- 2012-03-02 CL CL2012000591A patent/CL2012000591A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112012008109A2 (pt) | 2019-09-24 |
JP2013503833A (ja) | 2013-02-04 |
EA201200402A1 (ru) | 2012-08-30 |
SG178984A1 (en) | 2012-04-27 |
CR20120097A (es) | 2012-09-03 |
AU2010291318A1 (en) | 2012-03-01 |
CA2769553A1 (fr) | 2011-03-10 |
IL218253A0 (en) | 2012-04-30 |
ES2554855T3 (es) | 2015-12-23 |
KR20120061055A (ko) | 2012-06-12 |
EP2473486B2 (fr) | 2021-09-22 |
EP2473486B1 (fr) | 2015-10-28 |
US20120202806A1 (en) | 2012-08-09 |
DOP2012000057A (es) | 2012-08-31 |
MX2012002626A (es) | 2012-04-20 |
CN102482232A (zh) | 2012-05-30 |
TN2012000045A1 (en) | 2013-09-19 |
WO2011026835A1 (fr) | 2011-03-10 |
AR077999A1 (es) | 2011-10-05 |
EP2473486A1 (fr) | 2012-07-11 |
TW201113272A (en) | 2011-04-16 |
CL2012000591A1 (es) | 2012-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33538B1 (fr) | Nouveaux antagonistes pyrimidine et triazine de l'hepcidine | |
MA32226B1 (fr) | Compositions et leurs procedes de preparation et d'utilisation | |
BR112013020916A2 (pt) | compostos de fórmula geral, composição e preparação combinada | |
MA31867B1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
MA30914B1 (fr) | Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques. | |
MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
MA33123B1 (fr) | 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation | |
MA33119B1 (fr) | Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase | |
MA30514B1 (fr) | Nouveaux composes. | |
MA38276B1 (fr) | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. | |
MA32466B1 (fr) | Derives de triazole utiles pour le traitement de maladies | |
MA33604B1 (fr) | Composés et compositions en tant qu'inhibiteurs de protéine kinase | |
MA31845B1 (fr) | Pipéridino-dihydrothiénopyrimidines substituées | |
MA32070B1 (fr) | Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés | |
MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
MA33920B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide | |
MA35039B1 (fr) | Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation | |
UA99132C2 (ru) | Производные дикарбоновых кислот как агонисты рецепторов s1p1 | |
MA31283B1 (fr) | Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse | |
MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
MA31949B1 (fr) | Dérivés d'aminotriazole comme agonistes d'alx | |
MA32798B1 (fr) | Acides naphtylacétiques |